Published: Nov 18, 2021 Reuters
BEIJING, Nov 18 (Reuters) - AstraZeneca Plc's (AZN.L) COVID-19
vaccine partner in China, Shenzhen Kangtai Biological Products
(BioKangtai) (300601.SZ), has begun its first shipment of the shot, sending
more than four million doses to Indonesia, BioKangtai said on Friday.
first batch, BioKangtai plans to send over eight million doses of the
China-made AstraZeneca shot, branded as KconecaVac, to Indonesia this month,
Zhang Qian, general manager at BioKangtai's international affairs department,
said in a video interview with local media.
the right to manufacture the vaccine, and the right to sell it in mainland
China, Indonesia and Pakistan.
hasn't begun clinical trials in China, which AstraZeneca hoped to start last
year before the application for local regulatory approval for the shot.
BioKangtai, which has its own COVID-19 vaccine approved by China, hasn't said
why trials for the AstraZeneca shot have been delayed.
companies including AstraZeneca and BioNTech have partnered with Chinese firms
to bring their shots to the country, but China has not allowed the use of any
coronavirus vaccines developed and approved overseas.
said in February its facility dedicated to making the AstraZeneca shot was expected
to reach an annual production capacity of 400 million doses. Its actual
production rate remains unclear.
has already shipped about 10 million doses of its COVID-19 vaccine to Indonesia
as of October, according to Indonesia's health ministry. The Southeast Asian
country has also received the vaccine through the global vaccine sharing scheme
View original source:
China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
COVID-19: A Basic Guide to Different Vaccine Types and How They Work
With global push for COVID-19 vaccines, China aims to win friends and cut deals